Appendix 1: Supporting References for Figure 1
41. Konecny M, Vizvaryova M, Weismanova E et al: The spectrum and incidence
of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families.
Neoplasma 2007; 54: 137-142.
42. Tomka M, Sedlakova O, Reinerova M et al: Mutation screening of the BRCA1
gene in Slovak patients. Neoplasma 2001; 48: 451-455.
43. Machackova E, Foretova L, Lukesova M et al: Spectrum and characterisation of
BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with
breast and/or ovarian cancer. BMC Cancer 2008; 8: 140.
44. Zikan M, Pohlreich P, Stribrna J: Mutational analysis of the BRCA1 gene in 30
Czech ovarian cancer patients. J Genet 2005; 84: 63-67.
45. Pohlreich P, Zikan M, Stribrna J et al: High proportion of recurrent germline
mutations in the BRCA1 gene in breast and ovarian cancer patients from the
Prague area. Breast Cancer Res 2005; 7: R728-R736.
46. Foretova L, Machackova E, Navratilova M et al: BRCA1 and BRCA2 mutations
in women with familial or early-onset breast/ovarian cancer in the Czech
Republic. Hum Mutat 2004; 23: 397-398.
47. Pohlreich P, Stribrna J, Kleibl Z et al: Mutations of the BRCA1 gene in
hereditary breast and ovarian cancer in the Czech Republic. Med Princ Pract
2003; 12: 23-29.
48. Machackova E, Foretova L, Navratilova M, Valik D, Claes K, Messiaen L: A
high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary
breast and breast-ovarian cancer families. Cas Lek Cesk 2000; 139: 635-637.
1
49. Smirnova TY, Pospekhova NI, Lyubchenko LN et al: High incidence of
mutations in BRCA1 and BRCA2 genes in ovarian cancer. Bull Exp Biol Med
2007; 144: 83-85.
50. Grudinina NA, Golubkov VI, Tikhomirova OS et al: [Prevalence of widespread
BRCA1 gene mutations in patients with familial breast cancer from St.
Petersburg]. Genetika 2005; 41: 405-410.
51. Loginova AN, Pospekhova NI, Lyubchenko LN et al: Spectrum of mutations in
BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian
families. Bull Exp Biol Med 2003; 136: 276-278.
52. Tereschenko IV, Basham VM, Ponder BA, Pharoah PD: BRCA1 and BRCA2
mutations in Russian familial breast cancer. Hum Mutat 2002; 19: 184.
53. Gayther SA, Harrington P, Russell P, Kharkevich G, Garkavtseva RF, Ponder
BA: Frequently occurring germ-line mutations of the BRCA1 gene in ovarian
cancer families from Russia. Am J Hum Genet 1997; 60: 1239-1242.
54. Tamboom K, Kaasik K, Arsavskaja J et al: BRCA1 mutations in women with
familial or early-onset breast cancer and BRCA2 mutations in familial cancer in
Estonia. Hered Cancer Clin Pract 2010; 8: 4.
55. Sobczak K, Kozlowski P, Napierala M et al: Novel BRCA1 mutations and more
frequent intron-20 alteration found among 236 women from Western Poland.
Oncogene 1997; 15: 1773-1779.
56. Grzybowska E, Zientek H, Jasinska A et al: High frequency of recurrent
mutations in BRCA1 and BRCA2 genes in Polish families with breast and
ovarian cancer. Hum Mutat 2000; 16: 482-490.
2
57. Gorski B, Byrski T, Huzarski T et al: Founder mutations in the BRCA1 gene in
Polish families with breast-ovarian cancer. Am J Hum Genet 2000; 66: 19631968.
58. van der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E: Founder
BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or
ovarian cancer families from North-Eastern Poland. Hum Mutat 2000; 15: 480481.
59. Jakubowska A, Gorski B, Byrski T et al: Detection of germline mutations in the
BRCA1 gene by RNA-based sequencing. Hum Mutat 2001; 18: 149-156.
60. Perkowska M, Brozek I, Wysocka B et al: BRCA1 and BRCA2 mutation
analysis in breast-ovarian cancer families from northeastern Poland. Hum Mutat
2003; 21: 553-554.
61. Gorski B, Jakubowska A, Huzarski T et al: A high proportion of founder
BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110: 683686.
62. Byrski T: [Germline mutation of BRCA1 gene in Polish families with strong
aggregation of breast and/or ovarian cancer based on coding sequence analysis
using the SSCP method]. Ann Acad Med Stetin 2003; 49: 27-43.
63. Ratajska M, Brozek I, Senkus-Konefka E et al: BRCA1 and BRCA2 point
mutations and large rearrangements in breast and ovarian cancer families in
Northern Poland. Oncol Rep 2008; 19: 263-268.
64. Papp J, Raicevic L, Milasin J, Dimitrijevic B, Radulovic S, Olah E: Germline
mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian
cancer families. Oncol Rep 1999; 6: 1435-1438.
3
65. Wagner TM, Moslinger RA, Muhr D et al: BRCA1-related breast cancer in
Austrian breast and ovarian cancer families: specific BRCA1 mutations and
pathological characteristics. Int J Cancer 1998; 77: 354-360.
66. van der Looij M, Szabo C, Besznyak I et al: Prevalence of founder BRCA1 and
BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J
Cancer 2000; 86: 737-740.
67. Ramus SJ, Kote-Jarai Z, Friedman LS et al: Analysis of BRCA1 and BRCA2
mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum
Genet 1997; 60: 1242-1246.
68. Janavicius R, Pepalyte I, Kucinskas V: Novel and common BRCA1 mutations in
familial breast/ovarian cancer patients from Lithuania. Breast Cancer Res Treat
2009; 117: 467-469.
69. Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A: High
prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam
Cancer 2005; 4: 77-84.
70. Csokay B, Tihomirova L, Stengrevics A, Sinicka O, Olah E: Strong founder
effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation
in brief no. 258. Online. Hum Mutat 1999; 14: 92.
71. Hamann U, Liu X, Bungardt N, Ulmer HU, Bastert G, Sinn HP: Similar
contributions of BRCA1 and BRCA2 germline mutations to early-onset breast
cancer in Germany. Eur J Hum Genet 2003; 11: 464-467.
72. Balz V, Prisack HB, Bier H, Bojar H: Analysis of BRCA1, TP53, and TSG101
germline mutations in German breast and/or ovarian cancer families. Cancer
Genet Cytogenet 2002; 138: 120-127.
4
73. Meindl A: Comprehensive analysis of 989 patients with breast or ovarian cancer
provides BRCA1 and BRCA2 mutation profiles and frequencies for the German
population. Int J Cancer 2002; 97: 472-480.
74. Steinmann D, Bremer M, Rades D et al: Mutations of the BRCA1 and BRCA2
genes in patients with bilateral breast cancer. Br J Cancer 2001; 85: 850-858.
75. Hamann U, Brauch H, Garvin AM, Bastert G, Scott RJ: German family study on
hereditary breast and/or ovarian cancer: germline mutation analysis of the
BRCA1 gene. Genes Chromosomes Cancer 1997; 18: 126-132.
76. Hamann U, Haner M, Stosiek U, Bastert G, Scott RJ: Low frequency of BRCA1
germline mutations in 45 German breast/ovarian cancer families. J Med Genet
1997; 34: 884-888.
77. Dong J, Chang-Claude J, Wu Y et al: A high proportion of mutations in the
BRCA1 gene in German breast/ovarian cancer families with clustering of
mutations in the 3' third of the gene. Hum Genet 1998; 103: 154-161.
78. Hampl M, Hampl JA, Schwarz P et al: Accumulation of genetic alterations in
brain metastases of sporadic breast carcinomas is associated with reduced
survival after metastasis. Invasion Metastasis 1998; 18: 81-95.
79. Caligo MA, Ghimenti C, Cipollini G et al: BRCA1 germline mutational
spectrum in Italian families from Tuscany: a high frequency of novel mutations.
Oncogene 1996; 13: 1483-1488.
80. Curci A, Capasso I, Romano A et al: Characterization of 2 novel and 2 recurring
BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the
area of Naples. Int J Oncol 2002; 20: 963-970.
5
81. Ottini L, D'Amico C, Noviello C et al: BRCA1 and BRCA2 mutations in central
and southern Italian patients. Breast Cancer Res 2000; 2: 307-310.
82. Stuppia L, Di FP, Aceto G et al: BRCA1 and BRCA2 mutations in
breast/ovarian cancer patients from central Italy. Hum Mutat 2003; 22: 178-179.
83. Aretini P, D'Andrea E, Pasini B et al: Different expressivity of BRCA1 and
BRCA2: analysis of 179 Italian pedigrees with identified mutation. Breast
Cancer Res Treat 2003; 81: 71-79.
84. Santarosa M, Viel A, Dolcetti R et al: Low incidence of BRCA1 mutations
among Italian families with breast and ovarian cancer. Int J Cancer 1998; 78:
581-586.
85. Santarosa M, Dolcetti R, Magri MD et al: BRCA1 and BRCA2 genes: role in
hereditary breast and ovarian cancer in Italy. Int J Cancer 1999; 83: 5-9.
86. Papi L, Putignano AL, Congregati C et al: Founder mutations account for the
majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a
population from Tuscany, Central Italy. Breast Cancer Res Treat 2008.
87. Musolino A, Bella MA, Bortesi B et al: BRCA mutations, molecular markers,
and clinical variables in early-onset breast cancer: a population-based study.
Breast 2007; 16: 280-292.
88. Russo A, Calo V, Agnese V et al: BRCA1 genetic testing in 106 breast and
ovarian cancer families from Southern Italy (Sicily): a mutation analyses. Breast
Cancer Res Treat 2007; 105: 267-276.
89. Capalbo C, Ricevuto E, Vestri A et al: BRCA1 and BRCA2 genetic testing in
Italian breast and/or ovarian cancer families: mutation spectrum and prevalence
6
and analysis of mutation prediction models. Ann Oncol 2006; 17 Suppl 7: vii34vii40.
90. Belogianni I, Apessos A, Mihalatos M et al: Characterization of a novel large
deletion and single point mutations in the BRCA1 gene in a Greek cohort of
families with suspected hereditary breast cancer. BMC Cancer 2004; 4: 61.
91. Konstantopoulou I, Kroupis C, Ladopoulou A et al: BRCA1 mutation analysis
in breast/ovarian cancer families from Greece. Hum Mutat 2000; 16: 272-273.
92. Ladopoulou A, Kroupis C, Konstantopoulou I et al: Germ line BRCA1 &
BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most
frequent mutation observed. Cancer Lett 2002; 185: 61-70.
93. Armaou S, Pertesi M, Fostira F et al: Contribution of BRCA1 germ-line
mutations to breast cancer in Greece: a hospital-based study of 987 unselected
breast cancer cases. Br J Cancer 2009; 101: 32-37.
94. Konstantopoulou I, Rampias T, Ladopoulou A et al: Greek BRCA1 and BRCA2
mutation spectrum: two BRCA1 mutations account for half the carriers found
among high-risk breast/ovarian cancer patients. Breast Cancer Res Treat 2008;
107: 431-441.
95. Papelard H, de Bock GH, van ER et al: Prevalence of BRCA1 in a hospitalbased population of Dutch breast cancer patients. Br J Cancer 2000; 83: 719724.
96. Peelen T, van VM, Petrij-Bosch A et al: A high proportion of novel mutations in
BRCA1 with strong founder effects among Dutch and Belgian hereditary breast
and ovarian cancer families. Am J Hum Genet 1997; 60: 1041-1049.
7
97. Claes K, Machackova E, De VM, Poppe B, De PA, Messiaen L: Mutation
analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and
identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G. Dis
Markers 1999; 15: 69-73.
98. Claes K, Poppe B, Coene I, Paepe AD, Messiaen L: BRCA1 and BRCA2
germline mutation spectrum and frequencies in Belgian breast/ovarian cancer
families. Br J Cancer 2004; 90: 1244-1251.
99. Goelen G, Teugels E, Bonduelle M, Neyns B, De GJ: High frequency of
BRCA1/2 germline mutations in 42 Belgian families with a small number of
symptomatic subjects. J Med Genet 1999; 36: 304-308.
100. Moller P, Borg A, Heimdal K et al: The BRCA1 syndrome and other inherited
breast or breast-ovarian cancers in a Norwegian prospective series. Eur J Cancer
2001; 37: 1027-1032.
101. Johannsson O, Ostermeyer EA, Hakansson S et al: Founding BRCA1 mutations
in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet
1996; 58: 441-450.
102. Hakansson S, Johannsson O, Johansson U et al: Moderate frequency of BRCA1
and BRCA2 germ-line mutations in Scandinavian familial breast cancer. Am J
Hum Genet 1997; 60: 1068-1078.
103. Zelada-Hedman M, Wasteson AB, Claro A et al: A screening for BRCA1
mutations in breast and breast-ovarian cancer families from the Stockholm
region. Cancer Res 1997; 57: 2474-2477.
104. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A: Family history of
breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-
8
based series of early-onset breast cancer. J Natl Cancer Inst 2001; 93: 12151223.
105. Malander S, Ridderheim M, Masback A et al: One in 10 ovarian cancer patients
carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in
Southern Sweden. Eur J Cancer 2004; 40: 422-428.
106. Bergman A, Flodin A, Engwall Y et al: A high frequency of germline BRCA1/2
mutations in western Sweden detected with complementary screening
techniques. Fam Cancer 2005; 4: 89-96.
107. Bergthorsson JT, Ejlertsen B, Olsen JH et al: BRCA1 and BRCA2 mutation
status and cancer family history of Danish women affected with multifocal or
bilateral breast cancer at a young age. J Med Genet 2001; 38: 361-368.
108. Thomassen M, Hansen TV, Borg A et al: BRCA1 and BRCA2 mutations in
Danish families with hereditary breast and/or ovarian cancer. Acta Oncol 2008;
47: 772-777.
109. Soegaard M, Kjaer SK, Cox M et al: BRCA1 and BRCA2 mutation prevalence
and clinical characteristics of a population-based series of ovarian cancer cases
from Denmark. Clin Cancer Res 2008; 14: 3761-3767.
110. Vehmanen P, Friedman LS, Eerola H et al: Low proportion of BRCA1 and
BRCA2 mutations in Finnish breast cancer families: evidence for additional
susceptibility genes. Hum Mol Genet 1997; 6: 2309-2315.
111. Huusko P, Paakkonen K, Launonen V et al: Evidence of founder mutations in
Finnish BRCA1 and BRCA2 families. Am J Hum Genet 1998; 62: 1544-1548.
9
112. Hartikainen JM, Kataja V, Pirskanen M et al: Screening for BRCA1 and
BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet
2007; 72: 311-320.
113. Esteban CE, Bolufer GP, Palanca SS et al: [BRCA1 and BRCA2 mutations in
families studied in the program of genetic counselling in cancer of the Valencian
community (Spain)]. Med Clin (Barc ) 2008; 130: 121-126.
114. Martinez-Ferrandis JI, Vega A, Chirivella I et al: Mutational analysis of BRCA1
and BRCA2 in Mediterranean Spanish women with early-onset breast cancer:
identification of three novel pathogenic mutations. Hum Mutat 2003; 22: 417418.
115. Diez O, Osorio A, Duran M et al: Analysis of BRCA1 and BRCA2 genes in
Spanish breast/ovarian cancer patients: a high proportion of mutations unique to
Spain and evidence of founder effects. Hum Mutat 2003; 22: 301-312.
116. Blesa JR, Garcia JA, Ochoa E: Frequency of germ-line BRCA1 mutations
among Spanish families from a Mediterranean area. Hum Mutat 2000; 15: 381382.
117. Beristain E, Martinez-Bouzas C, Guerra I et al: Differences in the frequency and
distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases
from the Basque country with respect to the Spanish population: implications for
genetic counselling. Breast Cancer Res Treat 2007; 106: 255-262.
118. Velasco SE, Esteban CE, Infante SM et al: [Molecular study of the BRCA1 and
BRCA2 genes in 153 breast cancer families from Castilla and Leon (Spain): new
nine unclassified variants identified]. Med Clin (Barc ) 2002; 119: 441-445.
10
119. Miramar MD, Calvo MT, Rodriguez A et al: Genetic analysis of BRCA1 and
BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel
truncating mutations and a large genomic deletion in BRCA1. Breast Cancer
Res Treat 2008; 112: 353-358.
120. Duarte F, Cameselle-Teijeiro JF, Soares R et al: [Analysis of mutations in genes
BRCA1 and BRCA2 among patients with breast and ovarian cancer in northern
Portugal and Galicia]. Rev Clin Esp 2002; 202: 259-263.
121. Stoppa-Lyonnet D, Laurent-Puig P, Essioux L et al: BRCA1 sequence variations
in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie
Breast Cancer Group. Am J Hum Genet 1997; 60: 1021-1030.
122. Bonadona V, Sinilnikova OM, Chopin S et al: Contribution of BRCA1 and
BRCA2 germ-line mutations to the incidence of breast cancer in young women:
results from a prospective population-based study in France. Genes
Chromosomes Cancer 2005; 43: 404-413.
123. Peyrat JP, Vennin P, Hornez L, Bonneterre J: [Germ-line mutation of BRCA1 in
patients with breast and/or ovarian cancer in high risk families in Northern
France]. Bull Cancer 1997; 84: 41-46.
124. Rostagno P, Gioanni J, Garino E, Vallino P, Namer M, Frenay M: A mutation
analysis of the BRCA1 gene in 140 families from southeast France with a
history of breast and/or ovarian cancer. J Hum Genet 2003; 48: 362-366.
125. Muller D, Bonaiti-Pellie C, Abecassis J, Stoppa-Lyonnet D, Fricker JP: BRCA1
testing in breast and/or ovarian cancer families from northeastern France
identifies two common mutations with a founder effect. Fam Cancer 2004; 3:
15-20.
11
126. Fricker JP, Muller D, Cutuli B et al: [Germ-line mutations of the BRCA1 gene
in northeastern France]. Bull Cancer 2000; 87: 739-744.
127. Uhrhammer N, Abdelouahab A, Lafarge L, Feillel V, Ben DA, Bignon YJ:
BRCA1 mutations in Algerian breast cancer patients: high frequency in young,
sporadic cases. Int J Med Sci 2008; 5: 197-202.
128. Yazici H, Glendon G, Yazici H et al: BRCA1 and BRCA2 mutations in Turkish
familial and non-familial ovarian cancer patients: a high incidence of mutations
in non-familial cases. Hum Mutat 2002; 20: 28-34.
129. Yazici H, Bitisik O, Akisik E et al: BRCA1 and BRCA2 mutations in Turkish
breast/ovarian families and young breast cancer patients. Br J Cancer 2000; 83:
737-742.
130. Ozdag H, Tez M, Sayek I et al: Germ line BRCA1 and BRCA2 gene mutations
in Turkish breast cancer patients. Eur J Cancer 2000; 36: 2076-2082.
131. Manguoglu AE, Luleci G, Ozcelik T et al: Germline mutations in the BRCA1
and BRCA2 genes in Turkish breast/ovarian cancer patients. Hum Mutat 2003;
21: 444-445.
132. Balci A, Huusko P, Paakkonen K et al: Mutation analysis of BRCA1 and
BRCA2 in Turkish cancer families: a novel mutation BRCA2 3414del4 found in
male breast cancer. Eur J Cancer 1999; 35: 707-710.
133. Egeli U, Cecener G, Tunca B, Tasdelen I: Novel germline BRCA1 and BRCA2
mutations in Turkish women with breast and/or ovarian cancer and their
relatives. Cancer Invest 2006; 24: 484-491.
12